Grindeks forecasts $17 million earning this year
This article was originally published in Scrip
Executive Summary
Latvia's largest pharmaceutical manufacturer Grindeks has forecasted Lt10 million ($17.2 million) annual earnings this year on the grounds of successive sales in the first five months. It said it has already achieved significant sales growth in the first five months in Latvia (+30%) and several foreign markets including Moldova (+66%), Ukraine (+30%) and Kazakhstan (+18%).